-- DBMS: bigquery
CREATE TABLE `isb-cgc-bq.HTAN_versioned.clinical_tier1_diagnosis_r4`
(
  ISS_Stage STRING OPTIONS(description="The multiple myeloma disease stage at diagnosis."),
  Tumor_Depth STRING OPTIONS(description="Numeric value that represents the depth of tumor invasion, measured in millimeters (mm)."),
  Residual_Disease STRING OPTIONS(description="Text terms to describe the status of a tissue margin following surgical resection."),
  International_Prognostic_Index STRING OPTIONS(description="The text term used to describe the International Prognostic Index, which classifies the prognosis of patients with aggressive non-Hodgkin's lymphoma."),
  Days_to_Last_Known_Disease_Status STRING OPTIONS(description="Time interval from the date of last follow up to the date of initial pathologic diagnosis, represented as a calculated number of days. If not applicable please enter 'Not Applicable'"),
  Primary_Gleason_Grade STRING OPTIONS(description="The text term used to describe the primary Gleason score, which describes the pattern of cells making up the largest area of the tumor. The primary and secondary Gleason pattern grades are combined to determine the patient's Gleason grade group, which is used to determine the aggresiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing."),
  IRS_Group STRING OPTIONS(description="Text term used to describe the classification of rhabdomyosarcoma tumors, as defined by the Intergroup Rhabdomyosarcoma Study (IRS)."),
  AJCC_Clinical_M STRING OPTIONS(description="Extent of the distant metastasis for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment."),
  Lymphatic_Invasion_Present STRING OPTIONS(description="A yes/no indicator to ask if small or thin-walled vessel invasion is present, indicating lymphatic involvement"),
  Lymph_Nodes_Tested STRING OPTIONS(description="The number of lymph nodes tested to determine whether lymph nodes were involved with disease as determined by a pathologic examination."),
  Anaplasia_Present STRING OPTIONS(description="Yes/no/unknown/Not Reported indicator used to describe whether anaplasia was present at the time of diagnosis."),
  Gleason_Grade_Tertiary STRING OPTIONS(description="The text term used to describe the tertiary pattern as described by the Gleason Grading System."),
  AJCC_Clinical_N STRING OPTIONS(description="Extent of the regional lymph node involvement for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment."),
  Breslow_Thickness STRING OPTIONS(description="The number that describes the distance, in millimeters, between the upper layer of the epidermis and the deepest point of tumor penetration."),
  Progression_or_Recurrence_Type STRING OPTIONS(description="The text term used to describe the type of progressive or recurrent disease or relapsed disease."),
  Days_to_Progression STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease progressed. If not applicable please enter 'Not Applicable'"),
  Margin_Distance STRING OPTIONS(description="Numeric value (in centimeters) that represents the distance between the tumor and the surgical margin."),
  Cog_Neuroblastoma_Risk_Group STRING OPTIONS(description="Text term that represents the categorization of patients on the basis of prognostic factors per a system developed by Children's Oncology Group (COG). Risk level is used to assign treatment intensity."),
  Prior_Treatment STRING OPTIONS(description="A yes/no/unknown/not applicable indicator related to the administration of therapeutic agents received before the body specimen was collected."),
  INSS_Stage STRING OPTIONS(description="Text term used to describe the staging classification of neuroblastic tumors, as defined by the International Neuroblastoma Staging System (INSS)."),
  Days_to_Last_Follow_up STRING OPTIONS(description="Time interval from the date of last follow up to the date of initial pathologic diagnosis, represented as a calculated number of days. If not applicable please enter 'Not Applicable'"),
  Greatest_Tumor_Dimension STRING OPTIONS(description="Numeric value that represents the measurement of the widest portion of the tumor in centimeters."),
  Synchronous_Malignancy STRING OPTIONS(description="A yes/no/unknown indicator used to describe whether the patient had an additional malignant diagnosis at the same time the tumor used for sequencing was diagnosed. If both tumors were sequenced, both tumors would have synchronous malignancies."),
  Tumor_Largest_Dimension_Diameter STRING OPTIONS(description="Numeric value used to describe the maximum diameter or dimension of the primary tumor, measured in centimeters."),
  Prior_Malignancy STRING OPTIONS(description="The yes/no/unknown indicator used to describe the patient's history of prior cancer diagnosis."),
  Days_to_Recurrence STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease recurred. If not applicable please enter 'Not Applicable'"),
  Tumor_Confined_to_Organ_of_Origin STRING OPTIONS(description="The yes/no/unknown indicator used to describe whether the tumor is confined to the organ where it originated and did not spread to a proximal or distant location within the body."),
  INPC_Histologic_Group STRING OPTIONS(description="The text term used to describe the classification of neuroblastomas distinguishing between favorable and unfavorable histologic groups. The histologic score, defined by the International Neuroblastoma Pathology Classification (INPC), is based on age, mitosis-karyorrhexis index (MKI), stromal content and degree of tumor cell differentiation."),
  Micropapillary_Features STRING OPTIONS(description="The yes/no/unknown indicator used to describe whether micropapillary features were determined to be present."),
  Ovarian_Specimen_Status STRING OPTIONS(description="The text term used to describe the physical condition of the involved ovary."),
  entityId STRING OPTIONS(description="Synapse ID of entity"),
  Margins_Involved_Site STRING OPTIONS(description="The text term used to describe the anatomic sites that were involved in the survival margins."),
  Metastasis_at_Diagnosis STRING OPTIONS(description="The text term used to describe the extent of metastatic disease present at diagnosis."),
  IGCCCG_Stage STRING OPTIONS(description="The text term used to describe the International Germ Cell Cancer Collaborative Group (IGCCCG), a grouping used to further classify metastatic testicular tumors."),
  Primary_Diagnosis STRING OPTIONS(description="Text term used to describe the patient's histologic diagnosis, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O)."),
  Laterality STRING OPTIONS(description="For tumors in paired organs, designates the side on which the cancer originates."),
  Morphology STRING OPTIONS(description="The third edition of the International Classification of Diseases for Oncology, published in 2000 used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms. The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs. In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains. A system of numbered categories for representation of data."),
  Cog_Rhabdomyosarcoma_Risk_Group STRING OPTIONS(description="Text term used to describe the classification of rhabdomyosarcoma, as defined by the Children's Oncology Group (COG)."),
  Tumor_Grade STRING OPTIONS(description="Numeric value to express the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness."),
  Gross_Tumor_Weight STRING OPTIONS(description="Numeric value used to describe the gross pathologic tumor weight, measured in grams."),
  Perineural_Invasion_Present STRING OPTIONS(description="A yes/no indicator to ask if perineural invasion or infiltration of tumor or cancer is present."),
  Ovarian_Surface_Involvement STRING OPTIONS(description="The text term that describes whether the surface tissue (outer boundary) of the ovary shows evidence of involvement or presence of cancer."),
  Method_of_Diagnosis STRING OPTIONS(description="Text term used to describe the method used to confirm the patients malignant diagnosis."),
  Pregnant_at_Diagnosis STRING OPTIONS(description="The text term used to indicate whether the patient was pregnant at the time they were diagnosed."),
  Mitosis_Karyorrhexis_Index STRING OPTIONS(description="Text term that represents the component of the International Neuroblastoma Pathology Classification (INPC) for mitosis-karyorrhexis index (MKI)."),
  AJCC_Clinical_T STRING OPTIONS(description="Extent of the primary cancer based on evidence obtained from clinical assessment parameters determined prior to treatment."),
  Secondary_Gleason_Grade STRING OPTIONS(description="The text term used to describe the secondary Gleason score, which describes the pattern of cells making up the second largest area of the tumor. The primary and secondary Gleason pattern grades are combined to determine the patient's Gleason grade group, which is used to determine the aggresiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing."),
  Id STRING OPTIONS(description="Unique identifier of entity e.g. a96059eb-81af-4b24-ae50-9242c0d8f819"),
  Lymph_Node_Involved_Site STRING OPTIONS(description="The text term used to describe the anatomic site of lymph node involvement."),
  Metastasis_at_Diagnosis_Site STRING OPTIONS(description="Text term to identify an anatomic site in which metastatic disease involvement is found."),
  Tumor_Focality STRING OPTIONS(description="The text term used to describe whether the patient's disease originated in a single location or multiple locations."),
  First_Symptom_Prior_to_Diagnosis STRING OPTIONS(description="Text term used to describe the patient's first symptom experienced prior to diagnosis and thought to be related to the disease."),
  Last_Known_Disease_Status STRING OPTIONS(description="Text term that describes the last known state or condition of an individual's neoplasm."),
  Progression_or_Recurrence_Anatomic_Site STRING OPTIONS(description="The text term used to describe the anatomic site of resection; biopsy; tissue or organ of biospecimen origin; progression or recurrent disease; treatment"),
  Vascular_Invasion_Present STRING OPTIONS(description="The yes/no indicator to ask if large vessel or venous invasion was detected by surgery or presence in a tumor specimen."),
  Component STRING OPTIONS(description="Category of metadata (e.g. Diagnosis, Biospecimen, scRNA-seq Level 1, etc.); provide the same one for all items/rows."),
  Vascular_Invasion_Type STRING OPTIONS(description="Text term that represents the type of vascular tumor invasion."),
  AJCC_Pathologic_N STRING OPTIONS(description="The codes that represent the stage of cancer based on the nodes present (N stage) according to criteria based on multiple editions of the AJCC's Cancer Staging Manual."),
  INRG_Stage STRING OPTIONS(description="The text term used to describe the staging classification of neuroblastic tumors, as defined by the International Neuroblastoma Risk Group (INRG)."),
  WHO_NTE_Grade STRING OPTIONS(description="WHO NTE Grade"),
  Site_of_Resection_or_Biopsy STRING OPTIONS(description="The text term used to describe the anatomic site of the resection or biopsy of the patient's malignant disease, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O)."),
  Anaplasia_Present_Type STRING OPTIONS(description="The text term used to describe the morphologic findings indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample."),
  AJCC_Pathologic_Stage STRING OPTIONS(description="The extent of a cancer, especially whether the disease has spread from the original site to other parts of the body based on AJCC staging criteria."),
  AJCC_Clinical_Stage STRING OPTIONS(description="Stage group determined from clinical information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for cancer."),
  Year_of_Diagnosis STRING OPTIONS(description="Numeric value to represent the year of an individual's initial pathologic diagnosis of cancer."),
  Non_Nodal_Tumor_Deposits STRING OPTIONS(description="The yes/no/unknown indicator used to describe the presence of tumor deposits in the pericolic or perirectal fat or in adjacent mesentery away from the leading edge of the tumor."),
  Tissue_or_Organ_of_Origin STRING OPTIONS(description="The text term used to describe the anatomic site of origin, of the patient's malignant disease, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O)."),
  Age_at_Diagnosis STRING OPTIONS(description="Age at the time of diagnosis expressed in number of days since birth."),
  AJCC_Staging_System_Edition STRING OPTIONS(description="The text term used to describe the version or edition of the American Joint Committee on Cancer Staging Handbooks, a publication by the group formed for the purpose of developing a system of staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications."),
  INPC_Grade STRING OPTIONS(description="Text term used to describe the classification of neuroblastic differentiation within neuroblastoma tumors, as defined by the International Neuroblastoma Pathology Classification (INPC)."),
  Best_Overall_Response STRING OPTIONS(description="The best improvement achieved throughout the entire course of protocol treatment."),
  Medulloblastoma_Molecular_Classification STRING OPTIONS(description="The text term used to describe the classification of medulloblastoma tumors based on molecular features."),
  AJCC_Pathologic_M STRING OPTIONS(description="Code to represent the defined absence or presence of distant spread or metastases (M) to locations via vascular channels or lymphatics beyond the regional lymph nodes, using criteria established by the American Joint Committee on Cancer (AJCC)."),
  Gleason_Grade_Group STRING OPTIONS(description="The text term used to describe the overall grouping of grades defined by the Gleason grading classification, which is used to determine the aggressiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing."),
  Lymph_Nodes_Positive STRING OPTIONS(description="The number of lymph nodes involved with disease as determined by pathologic examination."),
  Gleason_Patterns_Percent STRING OPTIONS(description="Numeric value that represents the percentage of Patterns 4 and 5, which is used when the Gleason score is greater than 7 to predict prognosis."),
  WHO_CNS_Grade STRING OPTIONS(description="WHO CNS Grade"),
  AJCC_Pathologic_T STRING OPTIONS(description="Code of pathological T (primary tumor) to define the size or contiguous extension of the primary tumor (T), using staging criteria from the American Joint Committee on Cancer (AJCC)."),
  Days_to_Diagnosis STRING OPTIONS(description="Number of days between the date used for index and the date the patient was diagnosed with the malignant disease. If not applicable please enter 'Not Applicable'"),
  HTAN_Participant_ID STRING OPTIONS(description="HTAN ID associated with a patient based on HTAN ID SOP (eg HTANx_yyy )"),
  Progression_or_Recurrence STRING OPTIONS(description="Yes/No/unknown indicator to identify whether a patient has had a new tumor event after initial treatment."),
  IRS_Stage STRING OPTIONS(description="The text term used to describe the classification of rhabdomyosarcoma tumors, as defined by the Intergroup Rhabdomyosarcoma Study (IRS)."),
  Percent_Tumor_Invasion STRING OPTIONS(description="The percentage of tumor cells spread locally in a malignant neoplasm through infiltration or destruction of adjacent tissue."),
  Non_Nodal_Regional_Disease STRING OPTIONS(description="The text term used to describe whether the patient had non-nodal regional disease."),
  Days_to_Progression_Free STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease was formally confirmed as progression-free. If not applicable please enter 'Not Applicable'"),
  Classification_of_Tumor STRING OPTIONS(description="Text that describes the kind of disease present in the tumor specimen as related to a specific timepoint."),
  Peritoneal_Fluid_Cytological_Status STRING OPTIONS(description="The text term used to describe the malignant status of the peritoneal fluid determined by cytologic testing."),
  Mitotic_Count STRING OPTIONS(description="The number of mitoses identified under the microscope in tumors. The method of counting varies, according to the specific tumor examined. Usually, the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields."),
  Supratentorial_Localization STRING OPTIONS(description="Text term to specify the location of the supratentorial tumor."),
  HTAN_Center STRING OPTIONS(description="Name of HTAN Center e.g. HTAN HTAPP"),
  Manifest_Id STRING OPTIONS(description="Synapse ID of manifest containing file annotation"),
  Manifest_Version INT64 OPTIONS(description="Latest version of metadata manifest")
)
OPTIONS(
  friendly_name="HTAN CLINICAL TIER 1 DATA - DIAGNOSIS R4 VERSIONED",
  description="This table contains diagnostic clinical information about HTAN patient cases based on the NCI Genomic Data Commons (GDC) clinical data model. Data was extracted from HTAN Synapse projects in October 2023. More details: see https://data.humantumoratlas.org/standard/clinical",
  labels=[("access", "open"), ("data_type", "clinical_data"), ("program", "htan"), ("source", "htan"), ("category", "clinical_biospecimen_data"), ("status", "current")]
);

INSERT INTO `isb-cgc-bq.HTAN_versioned.clinical_tier1_diagnosis_r4` (ISS_Stage, Tumor_Depth, Residual_Disease, International_Prognostic_Index, Days_to_Last_Known_Disease_Status, Primary_Gleason_Grade, IRS_Group, AJCC_Clinical_M, Lymphatic_Invasion_Present, Lymph_Nodes_Tested, Anaplasia_Present, Gleason_Grade_Tertiary, AJCC_Clinical_N, Breslow_Thickness, Progression_or_Recurrence_Type, Days_to_Progression, Margin_Distance, Cog_Neuroblastoma_Risk_Group, Prior_Treatment, INSS_Stage, Days_to_Last_Follow_up, Greatest_Tumor_Dimension, Synchronous_Malignancy, Tumor_Largest_Dimension_Diameter, Prior_Malignancy, Days_to_Recurrence, Tumor_Confined_to_Organ_of_Origin, INPC_Histologic_Group, Micropapillary_Features, Ovarian_Specimen_Status, entityId, Margins_Involved_Site, Metastasis_at_Diagnosis, IGCCCG_Stage, Primary_Diagnosis, Laterality, Morphology, Cog_Rhabdomyosarcoma_Risk_Group, Tumor_Grade, Gross_Tumor_Weight, Perineural_Invasion_Present, Ovarian_Surface_Involvement, Method_of_Diagnosis, Pregnant_at_Diagnosis, Mitosis_Karyorrhexis_Index, AJCC_Clinical_T, Secondary_Gleason_Grade, Id, Lymph_Node_Involved_Site, Metastasis_at_Diagnosis_Site, Tumor_Focality, First_Symptom_Prior_to_Diagnosis, Last_Known_Disease_Status, Progression_or_Recurrence_Anatomic_Site, Vascular_Invasion_Present, Component, Vascular_Invasion_Type, AJCC_Pathologic_N, INRG_Stage, WHO_NTE_Grade, Site_of_Resection_or_Biopsy, Anaplasia_Present_Type, AJCC_Pathologic_Stage, AJCC_Clinical_Stage, Year_of_Diagnosis, Non_Nodal_Tumor_Deposits, Tissue_or_Organ_of_Origin, Age_at_Diagnosis, AJCC_Staging_System_Edition, INPC_Grade, Best_Overall_Response, Medulloblastoma_Molecular_Classification, AJCC_Pathologic_M, Gleason_Grade_Group, Lymph_Nodes_Positive, Gleason_Patterns_Percent, WHO_CNS_Grade, AJCC_Pathologic_T, Days_to_Diagnosis, HTAN_Participant_ID, Progression_or_Recurrence, IRS_Stage, Percent_Tumor_Invasion, Non_Nodal_Regional_Disease, Days_to_Progression_Free, Classification_of_Tumor, Peritoneal_Fluid_Cytological_Status, Mitotic_Count, Supratentorial_Localization, HTAN_Center, Manifest_Id, Manifest_Version) VALUES (NULL, NULL, NULL, NULL, '6573', NULL, NULL, NULL, 'No', NULL, 'unknown', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Not Allowed To Collect', NULL, '6573', NULL, NULL, NULL, 'No', 'Not Applicable', 'Yes', NULL, NULL, NULL, NULL, NULL, 'No Metastasis', NULL, 'Glioblastoma', NULL, '9440', NULL, 'G4', NULL, 'No', NULL, 'Autopsy', NULL, NULL, NULL, NULL, '14eab71a-1107-405a-b785-327ddb3f597d', NULL, NULL, 'unknown', 'Not Reported', 'With tumor', NULL, 'unknown', 'Diagnosis', 'unknown', NULL, NULL, NULL, 'Brain NOS', NULL, NULL, NULL, NULL, NULL, 'Brain NOS', '18250', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Grade IV', NULL, NULL, 'HTA12_113', 'No', NULL, NULL, NULL, NULL, 'unknown', NULL, NULL, 'Not Reported', 'HTAN WUSTL', 'syn52257039', 6), (NULL, NULL, NULL, NULL, '6573', NULL, NULL, NULL, 'No', NULL, 'unknown', NULL, NULL, NULL, 'Local', NULL, NULL, NULL, 'Not Allowed To Collect', NULL, '6573', NULL, NULL, NULL, 'No', '18249', 'Yes', NULL, NULL, NULL, NULL, NULL, 'No Metastasis', NULL, 'Astrocytoma anaplastic', NULL, '9401', NULL, 'G3', NULL, 'No', NULL, 'Autopsy', NULL, NULL, NULL, NULL, '6d349ef0-c8a9-432a-a2e2-e1fa718279c8', NULL, NULL, 'unknown', 'Not Reported', 'With tumor', 'Brain NOS', 'unknown', 'Diagnosis', 'unknown', NULL, NULL, NULL, 'Brain NOS', NULL, NULL, NULL, NULL, NULL, 'Brain NOS', '17155', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Grade III', NULL, NULL, 'HTA12_114', 'Yes - Progression or Recurrence', NULL, NULL, NULL, NULL, 'unknown', NULL, NULL, 'Not Reported', 'HTAN WUSTL', 'syn52257039', 6), (NULL, NULL, NULL, NULL, '6934', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '6934', NULL, NULL, NULL, NULL, '0', NULL, NULL, NULL, NULL, 'syn25126720', NULL, NULL, NULL, 'Ductal carcinoma in situ NOS', NULL, 'Cribriform, Solid', NULL, 'High Grade', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2fbc858d-1f59-48a7-994b-0caba22383a8', NULL, NULL, NULL, NULL, 'Tumor free', NULL, NULL, 'Diagnosis', NULL, NULL, NULL, NULL, 'Upper-outer quadrant of breast', NULL, NULL, NULL, '2006', NULL, 'Breast NOS', '26260.0', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'HTA6_7', 'No', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'HTAN Duke', 'syn39263335', 4), (NULL, NULL, NULL, NULL, '9182', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '9182', NULL, NULL, NULL, NULL, 'Not Applicable', NULL, NULL, NULL, NULL, 'syn25129104', NULL, NULL, NULL, 'Ductal carcinoma in situ NOS', NULL, 'unknown', NULL, 'High Grade', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'c620575c-c4dd-4bb5-aee3-c0aad9d7a8ad', NULL, NULL, NULL, NULL, 'Tumor free', NULL, NULL, 'Diagnosis', NULL, NULL, NULL, NULL, 'Breast NOS', NULL, NULL, NULL, '1989', NULL, 'Breast NOS', '19458.0', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'HTA6_1042', 'No', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'HTAN Duke', 'syn39263335', 4), (NULL, NULL, NULL, NULL, '9183', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '9183', NULL, NULL, NULL, NULL, 'Not Applicable', NULL, NULL, NULL, NULL, 'syn25129107', NULL, NULL, NULL, 'Ductal carcinoma in situ NOS', NULL, 'unknown', NULL, 'Low Grade', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'df0f40ce-0eb5-458f-8396-426c8d58f1ef', NULL, NULL, NULL, NULL, 'Tumor free', NULL, NULL, 'Diagnosis', NULL, NULL, NULL, NULL, 'Breast NOS', NULL, NULL, NULL, '1988', NULL, 'Breast NOS', '25966.0', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'HTA6_1076', 'No', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'HTAN Duke', 'syn39263335', 4);